Literature DB >> 34244612

Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.

Lasse S Kristensen1, Kirsten Grønbæk2,3,4, Mette Dahl5,6,7, Simon Husby5,6,7, Christian W Eskelund5,6, Søren Besenbacher8, Søren Fjelstrup9, Christophe Côme5,6,7, Sara Ek10, Arne Kolstad11, Riikka Räty12, Mats Jerkeman13, Christian H Geisler5, Jørgen Kjems9,14.   

Abstract

Mantle cell lymphoma (MCL) is characterized by marked differences in outcome, emphasizing the need for strong prognostic biomarkers. Here, we explore expression patterns and prognostic relevance of circular RNAs (circRNAs), a group of endogenous non-coding RNA molecules, in MCL. We profiled the circRNA expression landscape using RNA-sequencing and explored the prognostic potential of 40 abundant circRNAs in samples from the Nordic MCL2 and MCL3 clinical trials, using NanoString nCounter Technology. We report a circRNA-based signature (circSCORE) developed in the training cohort MCL2 that is highly predictive of time to progression (TTP) and lymphoma-specific survival (LSS). The dismal outcome observed in the large proportion of patients assigned to the circSCORE high-risk group was confirmed in the independent validation cohort MCL3, both in terms of TTP (HR 3.0; P = 0.0004) and LSS (HR 3.6; P = 0.001). In Cox multiple regression analysis incorporating MIPI, Ki67 index, blastoid morphology and presence of TP53 mutations, circSCORE retained prognostic significance for TTP (HR 3.2; P = 0.01) and LSS (HR 4.6; P = 0.01). In conclusion, circRNAs are promising prognostic biomarkers in MCL and circSCORE improves identification of high-risk disease among younger patients treated with cytarabine-containing chemoimmunotherapy and autologous stem cell transplant.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34244612     DOI: 10.1038/s41375-021-01311-4

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  55 in total

1.  Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Br J Haematol       Date:  2012-05-29       Impact factor: 6.998

2.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Authors:  Eva Hoster; Andreas Rosenwald; Françoise Berger; Heinz-Wolfram Bernd; Sylvia Hartmann; Christoph Loddenkemper; Thomas F E Barth; Nicole Brousse; Stefano Pileri; Grzegorz Rymkiewicz; Roman Kodet; Stephan Stilgenbauer; Roswitha Forstpointner; Catherine Thieblemont; Michael Hallek; Bertrand Coiffier; Ursula Vehling-Kaiser; Réda Bouabdallah; Lothar Kanz; Michael Pfreundschuh; Christian Schmidt; Vincent Ribrag; Wolfgang Hiddemann; Michael Unterhalt; Johanna C Kluin-Nelemans; Olivier Hermine; Martin H Dreyling; Wolfram Klapper
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

4.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.

Authors:  Markus Tiemann; Carsten Schrader; Wolfram Klapper; Martin H Dreyling; Elias Campo; Andrew Norton; Francoise Berger; Philip Kluin; German Ott; Stephano Pileri; Ennio Pedrinis; Alfred C Feller; Hartmut Merz; Dirk Janssen; Martin L Hansmann; Han Krieken; Peter Möller; Harald Stein; Michael Unterhalt; Wolfgang Hiddemann; Reza Parwaresch
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

5.  New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Authors:  David W Scott; Pau Abrisqueta; George W Wright; Graham W Slack; Anja Mottok; Diego Villa; Pedro Jares; Hilka Rauert-Wunderlich; Cristina Royo; Guillem Clot; Magda Pinyol; Merrill Boyle; Fong Chun Chan; Rita M Braziel; Wing C Chan; Dennis D Weisenburger; James R Cook; Timothy C Greiner; Kai Fu; German Ott; Jan Delabie; Erlend B Smeland; Harald Holte; Elaine S Jaffe; Christian Steidl; Joseph M Connors; Randy D Gascoyne; Andreas Rosenwald; Louis M Staudt; Elias Campo; Lisa M Rimsza
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

6.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

7.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Authors:  Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

8.  Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

Authors:  Dai Chihara; Chan Y Cheah; Jason R Westin; Luis E Fayad; Maria A Rodriguez; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Fernando Cabanillas; Hagop Kantarjian; Larry W Kwak; Michael L Wang; Jorge E Romaguera
Journal:  Br J Haematol       Date:  2015-12-09       Impact factor: 6.998

9.  15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Authors:  Christian W Eskelund; Arne Kolstad; Mats Jerkeman; Riikka Räty; Anna Laurell; Sandra Eloranta; Karin E Smedby; Simon Husby; Lone B Pedersen; Niels S Andersen; Mikael Eriksson; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Christopher T Workman; Christian Garde; Erkki Elonen; Peter Brown; Kirsten Grønbaek; Christian H Geisler
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

10.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Authors:  Olivier Hermine; Eva Hoster; Jan Walewski; André Bosly; Stephan Stilgenbauer; Catherine Thieblemont; Michal Szymczyk; Reda Bouabdallah; Michael Kneba; Michael Hallek; Gilles Salles; Pierre Feugier; Vincent Ribrag; Josef Birkmann; Roswitha Forstpointner; Corinne Haioun; Mathias Hänel; René Olivier Casasnovas; Jürgen Finke; Norma Peter; Kamal Bouabdallah; Catherine Sebban; Thomas Fischer; Ulrich Dührsen; Bernd Metzner; Georg Maschmeyer; Lothar Kanz; Christian Schmidt; Richard Delarue; Nicole Brousse; Wolfram Klapper; Elizabeth Macintyre; Marie-Hélène Delfau-Larue; Christiane Pott; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Journal:  Lancet       Date:  2016-06-14       Impact factor: 79.321

View more
  2 in total

Review 1.  The emerging roles of circRNAs in cancer and oncology.

Authors:  Lasse S Kristensen; Theresa Jakobsen; Henrik Hager; Jørgen Kjems
Journal:  Nat Rev Clin Oncol       Date:  2021-12-15       Impact factor: 66.675

Review 2.  Accentuating CircRNA-miRNA-Transcription Factors Axis: A Conundrum in Cancer Research.

Authors:  Deepti Singh; Prashant Kesharwani; Nabil A Alhakamy; Hifzur R Siddique
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.